– CANADA, Toronto – ProMIS Neurosciences, Inc. (TSX: PMN | OTC: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Dr. Maggie Shafmaster (Ph.D., JD) to its Board of Directors, with immediate effect.
“I am delighted to welcome Maggie Shafmaster as a member of the ProMIS Board of Directors at this time,” said Executive Chairman, Eugene Williams. “Maggie has been following our scientific progress for years and understands its unique potential. Her extensive experience with both offensive and defensive intellectual property strategies in the biotechnology and pharmaceutical sectors will be an important asset as we enter a potential rapid growth phase for the company. We look forward to Maggie’s expert guidance as we continue to expand and capitalize on the value of our IP portfolio at ProMIS.”
About Dr. Maggie Shafmaster
Dr. Maggie Shafmaster has over 25 years of experience providing intellectual property advice to the biotechnology and pharmaceutical industries. She was formerly SVP and Chief Patent Counsel at Genzyme, where she provided strategic guidance and IP advice for major commercial and research transactions and led a team responsible for the procurement, licensing defense, and enforcement of Genzyme’s worldwide intellectual property. Upon Genzyme’s acquisition by Sanofi, Maggie became VP and Chief Patent Counsel of Sanofi Pasteur. In 2014, Maggie became an independent consultant, providing strategic advice related to IP portfolio development, commercial transactions, and potential and ongoing patent and trade secret disputes.
“I am very pleased to join the Board of Directors of ProMIS,” commented Dr. Maggie Shafmaster. “ProMIS has developed an impressive intellectual property position around antibody-based therapeutics that are highly selective in targeting the toxic oligomers believed to be root causes of numerous neurodegenerative and other misfolded protein diseases. I look forward to working with the ProMIS Board of Directors to help maximize the potential of this exciting technology.”
Maggie holds a Ph.D. in Molecular Biology and Virology from Cornell University Graduate School of Medical Sciences and a JD summa cum laude from New York Law School.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. is a development-stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease, amyotrophic lateral sclerosis, and Parkinson’s disease. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS, and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For more information: https://promisneurosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
